Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy.

OBJECTIVE: The purpose of this study was to retrospectively investigate whether 3D breast density changes measured using MRI were associated with recurrent cancer in patients with breast cancer who received adjuvant tamoxifen. MATERIALS AND METHODS: A search of the breast MRI database (2007-2008) revealed a dataset that included 80 women (mean age, 44 years; range, 27-68 years) with breast cancer who underwent breast-conserving surgery, adjuvant tamoxifen treatment, and breast MRI before and after tamoxifen. The following clinicopathologic variables were collected: age, body mass index, menopausal status, family history, tumor stage, tumor grade, hormonal receptor status, and adjuvant chemotherapy status. MRI variables (total breast volume, fibro-glandular volume, and breast density) were measured for the contralateral untreated breast before and after tamoxifen treatment, and the percentage changes were recorded. A multivariate logistic regression analysis was performed to identify independent factors that were associated with cancer recurrence. RESULTS: Overall, 12 (15%) of the 80 women developed recurrence. No recurrent cancers were found in the remaining 68 patients (85%) at a median follow-up of 48 months (range, 37-60 months). Percentage reduction of breast density after tamoxifen was the only independent factor associated with recurrence (adjusted odds ratio [OR] = 0.848, 95% CI = 0.769-0.935, and p = 0.001 for observer 1; adjusted OR = 0.957, 95% CI = 0.919-0.996, and p = 0.032 for observer 2) in the multivariate analysis. CONCLUSION: Three-dimensional breast density changes measured using MRI during tamoxifen treatment were an independent factor associated with cancer recurrence in patients with breast cancer who received adjuvant tamoxifen.

Background ¹8F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.

UNLABELLED: We aimed to determine whether background (18)F-FDG uptake in positron emission mammography (PEM) was related to mammographic density or background parenchymal enhancement in breast MRI. METHODS: We studied a total of 52 patients (mean age, 50.9 years, 26 premenopausal, 26 postmenopausal) with newly diagnosed breast cancer who underwent (18)F-FDG PEM (positron emission mammography), conventional mammography and breast MRI. The background mean (18)F-FDG uptake value on PEM was obtained by drawing a user-defined region of interest (ROI) in a normal area of the contralateral breast. We reviewed the mammography retrospectively for overall breast density of contralateral breast according to the four-point scale (grade 1-4) of the Breast Imaging Reporting and Data System (BI-RADS) classification. The background parenchymal enhancement of breast MRI was classified as minimal, mild, moderate, or marked. All imaging findings were interpreted by two readers in consensus without knowledge of image findings of other modalities. RESULTS: Multiple linear regression analysis revealed a significant correlation between background (18)F-FDG uptake on PEM and mammographic density after adjustment for age and menopausal status (P<0.01), but not between background (18)F-FDG uptake on PEM and background parenchymal enhancement on MRI. CONCLUSION: Background (18)F-FDG uptake on PEM significantly increases as mammographic density increases. Background parenchymal enhancement in breast MRI was not an independent predictor of the background (18)F-FDG uptake on PEM unlike mammographic density.